The salvage pathway recycles NAD+ from nicotinamide and is the main route NMN feeds into. This article explains the biochemistry and why it matters for supplementation.
The NAD+ Salvage Pathway is the body's primary recycling system for maintaining nicotinamide adenine dinucleotide (NAD+) levels, a coenzyme that powers hundreds of metabolic reactions. Without this pathway, NAD+ pools would deplete rapidly, disrupting everything from mitochondrial ATP production to DNA repair enzyme activity. Understanding how this pathway works—and where it falters with age—helps explain why NAD+ precursor supplementation has become one of the most studied interventions in longevity research.
The Evidence Base
Human trials on NAD+ precursors have expanded significantly since 2020, though the literature remains weighted toward small, short-duration studies. The most rigorous data comes from randomized controlled trials (RCTs) in specific populations: prediabetic women, healthy older men, and amateur athletes. Animal and in vitro work provides mechanistic context, but translation to humans requires caution.
Yoshino et al. (2021) conducted a 10-week RCT in 25 postmenopausal women with prediabetes, showing that nicotinamide mononucleotide (NMN) at 250 mg daily improved muscle insulin sensitivity—a clinically meaningful endpoint. Igarashi et al. (2022) followed with a 12-week RCT in 65 healthy men aged 40–65, using 250 mg and 500 mg NMN doses, and found dose-dependent increases in blood NAD+ metabolites alongside changes in muscle function biomarkers. Irie et al. (2020) provided foundational pharmacokinetic data in 10 healthy Japanese men, demonstrating that oral NMN is well-tolerated and reliably elevates blood NAD+ levels. Liao et al. (2021) studied amateur runners with 300–1,200 mg NMN over six weeks, reporting enhanced aerobic capacity in the higher-dose groups. Niu et al. (2023) added a metabolic and telomere-focused perspective in a pre-aging cohort, though the study was shorter and exploratory in design.
Preclinical work by Gomes et al. (2013) established that declining NAD+ disrupts nuclear-mitochondrial communication via a pseudohypoxic state, providing a mechanistic rationale for why maintaining NAD+ matters. However, this research was conducted in mouse models, and the degree to which the same pseudohypoxic mechanism operates in humans remains uncertain.
The Mechanism
NAD+ is consumed constantly by three major enzyme classes: CD38 (immune signaling), sirtuins (epigenetic regulation), and PARPs (DNA repair). The NAD+ Salvage Pathway recycles the nicotinamide (NAM) byproduct of these reactions back into fresh NAD+, preventing net depletion. This recycling loop is not optional—it accounts for the vast majority of NAD+ maintenance in most mammalian tissues.
The pathway proceeds through a well-defined enzymatic sequence. NAM is first converted to nicotinamide mononucleotide (NMN) by the rate-limiting enzyme nicotinamide phosphoribosyltransferase (NAMPT). NMN is then adenylylated by NMN adenylyltransferase (NMNAT) to form NAD+. This two-step process is efficient but capacity-limited: NAMPT expression declines with age and is further suppressed by inflammation and metabolic stress.
Gomes et al. (2013) demonstrated that when NAD+ falls, the nuclear enzyme SIRT1 loses activity, leading to HIF-1α stabilization—a state that mimics hypoxia even under normal oxygen conditions. This pseudohypoxic state disrupts peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) signaling, impairing mitochondrial biogenesis and function. The implication is that NAD+ decline is not merely a marker of aging but a propagating factor that accelerates cellular dysfunction through impaired nuclear-mitochondrial communication.
Supplementing with NMN bypasses the NAMPT bottleneck, providing the immediate precursor that NMNAT converts directly to NAD+. This is distinct from supplementing with nicotinamide riboside (NR), which requires phosphorylation to NMN before entering the same final step. Both precursors ultimately converge on the salvage pathway, but NMN sits one enzymatic step closer to the end product.
Dosing and Study Outcomes: What the Human Data Shows
| Study | Population | Dose & Duration | Key Outcomes | Evidence Quality |
|---|---|---|---|---|
| Yoshino et al. (2021) | Prediabetic women (n=25) | 250 mg NMN, 10 weeks | Improved muscle insulin sensitivity | Moderate (single RCT) |
| Igarashi et al. (2022) | Healthy older men (n=65) | 250–500 mg NMN, 12 weeks | Elevated blood NAD+; altered muscle function markers | Moderate (RCT, dose-response) |
| Irie et al. (2020) | Healthy men (n=10) | 100–500 mg NMN, single and multiple doses | Well-tolerated; dose-dependent NAD+ metabolite increase | Limited (small, pharmacokinetic focus) |
| Liao et al. (2021) | Amateur runners (n=48) | 300–1,200 mg NMN, 6 weeks | Enhanced aerobic capacity at higher doses | Moderate (RCT, athletic population) |
| Niu et al. (2023) | Pre-aging adults (n=8) | 300 mg NMN, 8 weeks | Metabolic shifts; telomere length changes (exploratory) | Limited (very small, short duration) |
Two patterns emerge from this data. First, doses between 250 mg and 500 mg daily have been sufficient to raise blood NAD+ levels and produce measurable physiological changes in most studies. Second, higher doses (up to 1,200 mg) may confer additional benefits in specific contexts like aerobic performance, but the dose-response curve beyond 500 mg remains poorly characterized in general populations. For readers evaluating how to read supplement labels, these dose ranges provide a useful benchmark for comparing products.
It is worth noting that none of these studies were powered for long-term safety outcomes. The longest human trial to date is 12 weeks, and multi-year data on NMN supplementation does not exist. This is a genuine gap in the evidence, not a trivial limitation.
Who Benefits Most
The strongest human evidence for NMN supplementation currently sits in three overlapping groups: individuals with prediabetic insulin resistance, healthy middle-aged and older adults seeking to maintain metabolic function, and athletes looking to improve aerobic capacity. Yoshino et al. (2021) demonstrated that prediabetic women experienced improved muscle insulin sensitivity—an outcome with direct clinical relevance. Igarashi et al. (2022) and Irie et al. (2020) suggest that healthy older men reliably increase blood NAD+ with supplementation, though the functional significance of this elevation in otherwise healthy individuals requires more study.
Athletes represent a distinct use case. Liao et al. (2021) showed that amateur runners taking 600–1,200 mg NMN improved ventilatory threshold and oxygen utilization, effects most pronounced at the highest tested dose. This suggests that individuals with high aerobic demand may have a larger therapeutic window for NMN than sedentary populations, though the mechanism—whether mitochondrial, vascular, or both—has not been fully dissected.
People under chronic metabolic stress, such as those with obesity-related inflammation or disrupted circadian rhythms, may also have elevated NAD+ consumption through CD38 upregulation. In these cases, supporting the salvage pathway could theoretically help offset accelerated depletion. However, this is inferred from mechanistic studies rather than direct clinical trials, and human data in these specific populations is limited.
What the Evidence Doesn't Show
Despite enthusiastic marketing claims, several important questions remain unresolved. No human study has demonstrated that NMN supplementation extends lifespan. The longevity data is entirely preclinical, and translating mouse aging results to humans requires substantial caution. Similarly, no RCT has shown that NMN reverses established age-related disease in humans, reverses skin aging, or improves cognitive function in healthy adults.
The optimal dosing strategy is also unclear. Should NMN be taken in the morning to align with circadian NAMPT rhythms? Does cycling on and off supplementation preserve responsiveness? Should it be combined with resveratrol or other sirtuin activators? These are reasonable questions with no definitive human answers. For readers new to this space, our Supplement Beginner Guide covers how to approach evidence gaps like these without overcommitting to unproven stacks.
Another underexplored area is the relationship between oral NMN and tissue-specific NAD+ delivery. Blood NAD+ metabolites rise reliably after oral dosing, but whether this translates proportionally to NAD+ levels in muscle, brain, or liver varies by tissue and remains difficult to measure non-invasively in humans.
Practical Takeaways
- NMN is a direct precursor in the NAD+ Salvage Pathway, bypassing the age-declining NAMPT enzyme and feeding directly into NAD+ synthesis.
- Human RCTs show that 250–500 mg daily raises blood NAD+ levels and improves metabolic or performance markers in specific populations; higher doses up to 1,200 mg have been studied in athletes.
- The strongest evidence supports use in prediabetic individuals (insulin sensitivity), healthy older adults (metabolic maintenance), and amateur runners (aerobic capacity).
- Long-term safety data beyond 12 weeks is absent; NMN should be viewed as a promising but still-evolving intervention.
- Claims about lifespan extension, disease reversal, or dramatic anti-aging effects in humans are not supported by existing clinical trials.
- For those considering supplementation, selecting a form with verified purity and transparent labeling matters—this is where understanding bioavailability becomes relevant.
Bottom Line
The NAD+ Salvage Pathway is a genuine and important biochemical system, and NMN supplementation has demonstrated measurable effects on NAD+ levels and select metabolic outcomes in controlled human trials. The evidence is promising but narrow: it supports specific use cases in well-defined populations, not universal anti-aging claims. For individuals seeking to support NAD+ status through supplementation, products like Bio:sudo NMN 1000mg provide a dose that aligns with the upper ranges studied in human performance trials, though personal health context and realistic expectations should guide any decision to supplement.
References
- Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
- Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
- Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
- Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
- Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
- Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]